Oncotelic Therapeutics (Oncotelic Therapeutics) GF Value Rank : 0 (As of May. 05, 2024)

View and export this data going back to 1993. Start your Free Trial

What is Oncotelic Therapeutics GF Value Rank?

Oncotelic Therapeutics has the GF Value Rank of 0.

The GF Value Rank is determined by the price-to-GF-Value (P/GF Value) ratio, a proprietary metric calculated based on historical multiples along with an adjustment factor based on a company's past returns and growth and future estimates of the business' performance.

GuruFocus found that for valuation, we cannot simply give stocks a better GF Value rank simply because they have a lower P/GF Value ratio. Backtesting shows that over the long term, the two worst-performing groups are the most expensive group (with the highest P/GF Value ratio) and the least expensive group (with the lowest P/GF Value ratio).

We can understand why the most expensive group underperforms. We were initially puzzled by the underperformance of the least expensive group, but we realized there is a reason why some stocks are super cheap. If they look too undervalued, it is often because the businesses behind them are poor quality. The market realized this and gave them low valuations. In a way, the market is efficient.

After multiple backtesting analyses, we granted the stocks in third-cheapest percentile the highest GF Value rank, as they have performed the best over a full market cycle. Stock performance is actually not as sensitive to valuation as it is to growth and profitability. On average, the companies in the 20%-50% valuation groups have similar performances. Therefore, we should avoid the most expensive and the least expensive stocks. We can be more tolerant of valuation.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Oncotelic Therapeutics GF Value Rank Related Terms

Thank you for viewing the detailed overview of Oncotelic Therapeutics's GF Value Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Oncotelic Therapeutics (Oncotelic Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncotelic Therapeutics Inc (OTCPK:OTLC) » Definitions » GF Value Rank

Comparable Companies

Traded in Other Exchanges

N/A

Address

29397 Agoura Road, Suite 107, Agoura Hills, CA, USA, 91301

Website

https://www.oncotelic.com

Oncotelic Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing drugs for the treatment of orphan oncology indications, developing antisense and small molecule injectable drugs for the treatment of cancer with a focus on rare pediatric cancers, and addressing the current global pandemic. OT-101 is its lead immuno-oncology drug candidate. OT-101 also has activity against SARS-CoV-2. Its other products under pipeline are Artemisinin, CA4P, and Oxi4503. Currently, the company generates revenues from rendering services to other third-party customers for the development of certain drug products or in connection with certain out-licensing agreements.

Executives

Vuong Trieu	officer: CHIEF EXECUTIVE OFFICER	4003 JIM BOWIE ROAD, AGOURA HILLS CA 91301
Saran Saund	officer: CHIEF BUSINESS OFFICER	C/O MATEON THERAPEUTICS INC., 29397 AGOURA RD SUTIE 107, AGOURA HILLS CA 91301
Amit B. Shah	officer: CHIEF FINANCIAL OFFICER	10 AGUILA, ALISO VIEJO CA 92656
Chulho Park	officer: CHIEF TECHNOLOGY OFFICER	701 GATEWAY BOULEVARD, SUITE 210, SOUTH SAN FRANCISCO CA 94080
Maida Anthony E Iii	director	157 TECHNOLOGY DR, IRVINE CA 92618
Steven W King	director
David Diamond	director	29397 AGOURA RD., SUITE 107, AGOURA HILLS CA 91301
Fatih Uckun	10 percent owner, officer: Chief Medical Officer	701 GATEWAY BOULEVARD, SUITE 210, SOUTH SAN FRANCISCO CA 94080
Chao Hsiao	10 percent owner	701 GATEWAY BOULEVARD, SUITE 201, SOUTH SAN FRANCISCO CA 94080
Larn Hwang	10 percent owner	C/O MARINA BIOTECH, INC., 17870 CASTLETON STREET, SUITE 250, CITY OF INDUSTRY CA 91748
Donald Rogers Reynolds	director	C/O WYRICK ROBBINS YATES & PONTON LLP, 4101 LAKE BOONE TRAIL, SUITE 300, RALEIGH NC 27607
Sandage Bobby W Phd	director	C/O 99 HAYDEN AVE, 1 LEDGEMONT CENTER, LEXINGTON MA 02173
Simon Pedder	director	1001 MAIN STREET, SUITE 600, BUFFALO NY 14203
Matthew M Loar	officer: Chief Financial Officer	505 PENOBSCOT DR, REDWOOD CITY CA 94063
Pamela Ha	officer: Controller	701 GATEWAY BOULEVARD, SUITE 210, SOUTH SAN FRANCISCO CA 94080